LANCASTER, Pa., Oct. 4, 2018 /PRNewswire-PRWeb/ -- Smart Health Innovation Lab, a market adoption accelerator for healthcare
Emovi is a Montreal-based early-stage medical device company that has developed the KneeKG, a device that revolutionizes knee assessment by enabling doctors to accurately assess patients' knees in 3- D while the patient is moving and weight-bearing. NeuroFlow is a Philadelphia-based mental health technology company that has developed a platform to optimize mental wellness and enhance patient engagement between clinical sessions with a data-driven approach to brain health.
Developed collaboratively by Aspire Ventures, Capital BlueCross, Clio Health, and Penn Medicine Lancaster General Health, the goal of the Smart Health Innovation Lab is to advance cutting-edge technology aimed at improving health outcomes, lowering costs, and enhancing both the patient and provider experience.
"We are excited to have two exceptional companies graduate from our inaugural class," said Kim Ireland, CEO, Smart Health Innovation Lab. "The tremendous growth both companies have experienced throughout the course of the certification program underscores the value of the program and Smart Health Certification, and we look forward to the positive impact each company will make in the healthcare industry."
The lab's main initiative is to help market-ready technologies overcome the challenges associated with health system adoption and insurer reimbursement. During the program, Emovi and NeuroFlow worked closely with technology, payor, and clinical experts to help validate their products, integrate their technologies into clinical workflows, and gain adoption from providers and insurers.
"The Smart Health Certification Program has helped validate our product's usability at scale in a large health system and has accelerated our company's growth and expansion as a result," said Christopher Molaro, co-founder & CEO of NeuroFlow. "We're excited to be a part of a collaborative environment like the Smart Health Innovation Lab, where our technology has been able to make an immediate impact." Through a new partnership forged by the Smart Health Innovation Lab and Redox, graduates of the Smart Health Certification Program will have full access to Redox's integration platform, which will enable widespread electronic health record (EHR) interoperability with any health system. Resident and alumni companies can now overcome one of the biggest hurdles to healthcare technology market adoption: integration across major health systems.
"The Smart Health Certification Program is completely unique and the only program that creates a fast track to clinical adoption and integration, which we couldn't pass up," said Michelle Laflamme, CEO of Emovi. "The integration blueprint developed alongside Penn Medicine Lancaster General Health and Capital BlueCross will help us replicate the integration process into other health systems and reimbursement models."
Schedules for the class of 2019 are currently being developed. More details will follow later this fall. For more details on the Smart Health Innovation Lab and its founding organizations, resident companies, and more, please visit http://www.smarthealthinnovationlab.com.
About Smart Health Innovation Lab Smart Health Innovation Lab, located in Lancaster, Pa., is a market adoption accelerator built for testing, certifying, and advancing new healthcare technologies. At the lab, payors, providers, and technology companies work together in a unique collaboration to validate and integrate healthcare innovations into the healthcare marketplace. Founded by Aspire Ventures, Capital BlueCross, Clio Health, and Penn Medicine Lancaster General Health, the Smart Health Innovation Lab brings together different healthcare stakeholders to achieve a common goal: improving the health of our communities through new technologies that improve the patient and provider experience, lower cost of care, and improve health outcomes. For more information, visit http://www.smarthealthinnovationlab.com.
About Emovi Montreal, Quebec – An early-stage medical device company, Emovi has developed a breakthrough knee care system, KneeKG. The KneeKG device revolutionizes knee assessment by enabling doctors for the first time to accurately assess patients' knees in 3-D while the patient is moving and weight-bearing. In contrast to static information from x-ray and magnetic resonance imaging (MRI), KneeKG quickly identifies the functional causes linked to knee pain, allowing doctors to better target treatments instead of using the process of elimination. KneeKG can pinpoint functional deficits linked to knee osteoarthritis, ligament injuries, instabilities and anterior knee pain. By providing functional information to doctors with a higher correlation to symptoms and at a fraction of the cost of high-tech scans such as MRIs, the KneeKG allows doctors to significantly improve patients' quality of life, pain, and functional limitations.
About NeuroFlow Philadelphia, Pa. – A mental health technology company co-founded by a U.S. military veteran, NeuroFlow's HIPAA-compliant platform is used to optimize mental wellness and enhance patient engagement between clinical sessions with a data-driven approach to brain health. NeuroFlow boosts engagement by letting providers assign mental health exercises while encouraging patients to complete exercises with automated reminders and rewards for adherence. NeuroFlow also leverages real-time physiological data from wireless EEG and HRV sensors to measure relaxation and stress levels during specific exercises. NeuroFlow's unique solution for improving mental health patient engagement was recently voted the most innovative mental health technology by providers and healthcare experts at a Psych Congress pitch competition during the 2018 Elevate conference in Austin, Texas.
SOURCE Smart Health Innovation Lab
Subscribe to our Free Newsletters!